Neoplasms

All Conditions

Skin and Connective Tissue Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Rare Diseases

Carcinoma

Breast Neoplasms

Adenocarcinoma

Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Prostatic Neoplasms

Carcinoma, Renal Cell

Lung Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Urogenital Neoplasms

Urogenital Diseases

Male Urogenital Diseases

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Neoplasms

Urologic Neoplasms

Kidney Diseases

Urologic Diseases

Breast Diseases

Skin Diseases

Ovarian Cancer

Renal Cell Carcinoma

Ovarian Epithelial Cancer

Clear Cell Renal Cell Carcinoma

Antineoplastic Agents

All Drugs and Chemicals

Anti-Arrhythmia Agents

Vasodilator Agents

Analgesics

Immune Checkpoint Inhibitors

Immunomodulating Agents

Adenosine

Spartalizumab

Antineoplastic Agents, Immunological

Combination of NZV930 with NIR178 and PDR001

NZV930, Specified dose on specified days, intravenous (IV)

NZV930

PDR001, Specified dose on specified days, intravenous (IV)

PDR001

NIR178 Specified dose on specified days, Orally

NIR178

Novartis Pharmaceuticals

The purpose of this study was to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.

Incidence and severity of AEs and SAEs, incl. changes in laboratory parameters, vital signs, and ECGs Dose limiting toxicity in cycle 1 (28 days) for single agent NZV930 and NZV930 in combination with PDR001 and/or NIR178 during dose escalation phase only Tolerability: dose interruptions Tolerability: dose reductions Tolerability: dose intensity

Defined as the proportion of patients with best overall response of CR or PR

Defined as the proportion of patients with best overall response of CR, PR or SD \>= 16 weeks

Defined as the time from the date of start of treatment to the date of the event defined as first documented progression or death due to any cause

Serum concentration vs. time profiles of NZV930 (free drug) and PDR001.

Concentration time profile of NIR178 and its metabolites

Presence and titer of anti-drug antibodies, anti-NZV930 and anti-PDR001 in (patients receiving combination with PDR001).

Spots Global Cancer Trial Database for nzv930

Every month we try and update this database with for nzv930 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for nzv930

Every month we try and update this database with for nzv930 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for nzv930 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.